Dr Lopes presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that show front line pembrolizumab surpassed chemotherapy for lung cancer patients whose tumours had PD-L1 expression and no EGFR/ALK rearrangements.
For more on these results, watch his interview with ecancer and read our news coverage here.
Slides from this presentation are available here.